David is a partner and focuses on investments in novel therapeutics, often those that are near to first in human clinical testing.
Since joining Atlas Venture in 2010, David co-founded and served as chief executive officer of Arteaus Therapeutics, LLC which was acquired by Eli Lilly in 2014, co-founded and served as CEO of Annovation Biopharma Inc. which was acquired by The Medicines Company in early 2015, and was a founding board member of Delinia which was acquired by Celgene in early 2017. David is co-founder, founding chairman, and board member of Surface Oncology (NASDAQ: SURF), as well as co-founder and board member of Cadent Therapeutics, and board member of Xilio Therapeutics.
David serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the American Heart Association’s One Brave Idea, and is on the Scientific Advisory Board of the Tri-TDI that includes Rockefeller University, MSKCC, and Cornell.
Previously, David was a member of the executive team at Infinity Pharmaceuticals (NASDAQ: INFI) as the head of clinical development and medical affairs, as well as co-chairing the company’s scientific leadership team. David obtained his MD from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital. Prior to his medical training, he was a curriculum director at Stanford University Medical Center, where he created Stanford’s first case-based medical ethics curriculum. He received a BA with honors from Stanford University. David serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which he and his wife Courtney started in 2009.